Multi-country, multi-product MS support — at scale and without compromise
A global pharma brand needed end-to-end patient support across a complex MS portfolio spanning multiple countries, products, and patient journeys. RxPx built a single platform that delivered for all of them.
- 74% faster time to treatment — shortened from ~6 weeks to just 11–16 days
- 90% average adherence rates across all MS drugs in the PSP
- How RxPx solved titration complexity, self-injection confidence, and remote patient access simultaneously
Trusted by leading life sciences companies
Proven at scale.
A complex portfolio across multiple markets – and how RxPx unified it.
Multiple products, multiple countries, no unified solution
A global pharma brand’s MS portfolio spanned several products, each with unique routes of administration and patient journey challenges that varied significantly by country – creating a web of complexity no standard PSP could handle.
Complex titration portfolios and low patient confidence in self-injection
Rural and remote patients unable to access face-to-face care
National payer requirements slowing product uptake across markets
Patients required first-dose observation and titration navigation with no scalable solution
One personalized patient support portal built to flex across all of them
RxPx built a private, personalized app-based patient support portal that addressed every challenge simultaneously – delivering pre-screening, dosing, and adherence support across all products and markets from a single platform.
Personalized patient onboarding including pre-screening and first-dose observation support
Titration navigation and self-injection confidence building for complex regimens
Remote-accessible support eliminating the need for face-to-face visits
Multi-country deployment with country-specific payer and access pathways built in
Beyond the data.
Real feedback from patients across RxPx programs.
“We’ve had really great feedback from patients — thanks for making patient transitions onto medication so smooth, it’s been really amazing.”
“I can’t say enough — you have been amazing. I’m going to tell my Neurologist about this because everyone should be able to use the program.”
“For every 3 minutes it takes to enroll a patient, it saves 3 hours.”
What you’ll walk away knowing.
The multi-country platform architecture
How RxPx built one platform that flexed across multiple products, routes of administration, and national payer requirements simultaneously.
Why complex portfolios need a unified PSP
The hidden cost of fragmented support programs across multiple therapies – and how a unified approach changes the ROI equation.
Time to treatment and adherence outcomes
74% faster time to treatment, 90% average adherence, 92% patient satisfaction – the full results breakdown and what drove them.
How to apply this to your portfolio
A framework for evaluating where a unified, personalized patient portal can simplify your multi-product or multi-market PSP strategy.
A look at what you’ll discover.
The challenge: complexity at scale
Multiple MS products, multiple countries, multiple patient journeys — and why a standard PSP approach was never going to be enough.
The RxPx patient support portal
How RxPx designed a single, personalized portal to handle pre-screening, first-dose observation, titration navigation, and ongoing adherence support — across all products and markets.
Unlock full access
to case study.
Ready to see
the full results?
See exactly how RxPx cut time to treatment by 74% and achieved 90% adherence across a complex multi-country MS portfolio. Fill in your details below for instant access.
- 74% faster time to treatment — shortened from ~6 weeks to just 11–16 days
- 90% average adherence rates across all MS drugs in the PSP
- How RxPx solved titration complexity, self-injection confidence, and remote patient access simultaneously
Why Most Therapies Fail After Approval (And No One Talks About It)
Every pharmaceutical launch is measured against ambitious commercial forecasts.
How Do We Embrace AI Without Compromising Ethics, Governance, and Trust?
How Do We Embrace AI Without Compromising Ethics, Governance, and Trust?
The Industry Shift Emerging From AXS26: From Fragmentation to Integration
At Asembia AXS26, one message surfaced repeatedly across conversations with manufacturers, specialty pharmacies, hubs, and patient support leaders: healthcare fragmentation is becoming impossible to ignore.